EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
March 13 2017 - 7:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage specialty pharmaceutical company that
focuses on developing and commercializing products for treating
diseases and disorders of the eye, today announced the appointment
of two leading ophthalmology experts, Daniel S. Durrie, M.D. and
Randall J. Olson, M.D., to its Scientific Advisory Board (the
“SAB”). Drs. Durrie and Olson will work together with the other
members of EyeGate’s SAB to provide the Company strategic guidance
and support the continued development of its ophthalmic platforms,
EGP-437 and EyeGate OBG.
“We are proud to welcome Daniel and Randall to
the EyeGate’s SAB. They are both highly distinguished
ophthalmologists with a deep understanding of our target markets,”
said Stephen From, Chief Executive Officer of EyeGate. “We look
forward to leveraging their extensive scientific and clinical
expertise as we continue to advance our therapeutic candidates and
apply our highly innovative ophthalmic platforms to develop new
treatment options for patients in need.”
Daniel S. Durrie, M.D. has more than 30 years of
experience in refractive and corneal surgery and is a pioneer in
refractive surgery technology and procedures. He is a
board-certified ophthalmologist and currently serves as a Clinical
Professor and Director of Refractive Surgery Services at the
University of Kansas Medical Center. Dr. Durrie was named one of
the 50 “Most Influential Ophthalmologists in the World” by the
Cataract and Refractive Surgery Magazine. His research focuses on
advancements in vision correction technology. He has participated
in over 150 FDA clinical studies and has authored over 150
peer-reviewed scientific journal articles. He received his medical
degree and completed his ophthalmology residency at the University
of Nebraska, graduating with distinction. He completed a Corneal
Fellowship with Filkins Eye Institute in Omaha, Nebraska.
Randall J. Olson, M.D. is a board-certified
ophthalmologist with more than 30 years of experience. Currently,
he serves as Chief Executive Officer of the John A. Moran Eye
Center and Presidential Endowed Professor at University of Utah
School of Medicine. Dr. Olson specializes in research dealing with
cataract surgery, intra-ocular lens complications,
teleophthalmology and corneal transplantation techniques. He is the
author of more than 300 publications, and was selected as one of
the 15 best cataract surgeons in the United States by Ophthalmology
Times. He received his medical degree from University of Utah
School of Medicine and completed his residency in ophthalmology at
the University of California - Los Angeles.
About EyeGate:EyeGate is a
clinical-stage specialty pharmaceutical company that is focused on
developing and commercializing products for treating diseases and
disorders of the eye. EGP-437, EyeGate’s first product in clinical
trials, incorporates a reformulated topically active
corticosteroid, Dexamethasone Phosphate, that is delivered into the
ocular tissues through EyeGate’s proprietary innovative drug
delivery system, the EyeGate II Delivery System. In addition,
EyeGate is developing, through its wholly-owned Jade subsidiary,
products using cross-linked thiolated carboxymethyl hyaluronic acid
(“CMHA-S”), a modified form of the natural polymer hyaluronic acid
(HA), which possesses unique physical and chemical properties such
as hydration and healing properties. The ability of CMHA-S to
adhere longer to the ocular surface, resist degradation and protect
the ocular surface makes it well-suited for treating various ocular
surface injuries. For more information, please visit
www.EyeGatePharma.com.
Forward-looking Statements
Some of the statements in this press release
are “forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product and those
of Jade, a wholly owned subsidiary of EyeGate, as well as the
success thereof, with such approvals or success may not be obtained
or achieved on a timely basis or at all. These statements involve
risks and uncertainties that may cause results to differ materially
from the statements set forth in this press release, including,
among other things, certain risk factors described under the
heading “Risk Factors” contained in EyeGate’s Annual Report on Form
10-K filed with the SEC on February 23, 2017 or described in
EyeGate’s other public filings. EyeGate’s results may also be
affected by factors of which it is not currently aware. The
forward-looking statements in this press release speak only as of
the date of this press release. EyeGate expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is
based.
Contact:
Lee Roth / Janhavi Mohite
The Ruth Group for EyeGate Pharmaceuticals
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2023 to Apr 2024